Top-News

Neurocrine Biosciences Aktie News

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX Branche:  Pharmazeutika Land:  USA
155,51 $
+1,29 $
+0,84%
133,56 € 22:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
12,43 Mrd. €
Streubesitz
-
KGV
41,11
neu: Nachhaltigkeits-Score
40 %
Index-Zuordnung
-

Neurocrine Biosciences News

11.03.25 - PR Newswire
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum PR Newswire
05.03.25 - PR Newswire
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-​Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire
27.02.25 - PR Newswire
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
Neurocrine Biosciences Reports Patient-​Reported Outcome Data from KINECT-​PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically ...
25.02.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March PR Newswire
21.02.25 - PR Newswire
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program PR Newswire
06.02.25 - PR Newswire
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 PR Newswire
30.01.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results PR Newswire
28.01.25 - PR Newswire
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults ...
27.01.25 - PR Newswire
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) PR Newswire
23.01.25 - PR Newswire
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device PR Newswire
19.01.25 - Börse-Global
Neurocrine Biosciences Aktie: Positive Dynamik entfalten!
Die Neurocrine Biosciences Aktie zeigt sich Mitte Januar 2025 in einer überzeugenden Position am Markt. Der Aktienkurs erreichte am 18. Januar einen Stand von 143,26 USD, was ...
08.01.25 - PR Newswire
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism ...
06.01.25 - PR Newswire
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
20.12.24 - PR Newswire
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia PR Newswire
13.12.24 - PR Newswire
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-​in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia ...

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »